De Laffolie Jan, Ballauff Antje, Wirth Stefan, Blueml Carolin, Rommel Frank Risto, Claßen Martin, Laaß Martin, Lang Thomas, Hauer Almuthe Christina
Department of General Pediatrics and Neonatology, University of Giessen, Giessen, Germany.
Kinderklinik, Helios Klinikum Krefeld, Krefeld, Germany.
Front Pediatr. 2022 Jun 3;10:883183. doi: 10.3389/fped.2022.883183. eCollection 2022.
Among patients with inflammatory bowel disease (IBD), the risk of thromboembolism (TE) is increased, representing a relevant cause of morbidity and mortality. In contrast to other extraintestinal IBD manifestations, TE receives much less attention because of its low incidence, estimated at merely 0.4-0.9% in hospitalised children with IBD.
Cases with TE, as documented in the German-Austrian Paediatric IBD registry gesellschaft für pädiatrische gastroenterologie und ernährung - large paediatric patient registry (CEDATA-GPGE), were analyzed retrospectively. For all patients with signs of TE, a questionnaire was filled in by the treating paediatric gastroenterologist.
Over 10 years, 4,153 paediatric patients with IBD (0-18 years) were registered in the registry, and 12 of them identified with TE. Eight patients were diagnosed with ulcerative colitis (UC), three with Crohn's disease (CD), and one with IBD-unclassified. The median age at IBD diagnosis was 10 years and at the manifestation of TE 13 years, respectively, with a median latency to TE of 2 years. Prevalence of TE was 0.3%, with a significantly higher risk for patients with UC than CD (OR 5.9, CI 1.56-22.33, = 0.008). More girls than boys were affected (f:m = 7:5) without reaching significance. Approximately 90% of patients experienced TE during active disease, with relevant cerebral and limb involvement in 6/12 patients. Various risk factors, e.g., hospitalisation, coagulopathy, or anaemia were identified. TE management included intensive care and surgery. Among the 12 patients, 11 recovered fully, in which one patient has focal epilepsy as a sequela.
Paediatric patients with IBD have a substantially increased risk for TE. Risk factors, such as those identified should be considered when managing paediatric IBD and preventive measures for those hospitalised taken routinely. Initiating pharmacological thromboprophylaxis is challenging for the lack of published trials on efficacy and safety in paediatric IBD but should be considered carefully in each case.
炎症性肠病(IBD)患者发生血栓栓塞(TE)的风险增加,这是发病和死亡的一个相关原因。与其他肠外IBD表现不同,TE因其发病率低而受到的关注要少得多,据估计,住院的IBD儿童中TE的发病率仅为0.4 - 0.9%。
对德国 - 奥地利儿科IBD登记处gesellschaft für pädiatrische gastroenterologie und ernährung - 大型儿科患者登记处(CEDATA - GPGE)记录的TE病例进行回顾性分析。对于所有有TE迹象的患者,由治疗的儿科胃肠病学家填写一份问卷。
在10年期间,登记处登记了4153例IBD儿科患者(0 - 18岁),其中12例被确诊为TE。8例患者被诊断为溃疡性结肠炎(UC),3例为克罗恩病(CD),1例为未分类的IBD。IBD诊断时的中位年龄分别为10岁,TE出现时的中位年龄为13岁,TE的中位潜伏期为2年。TE的患病率为0.3%,UC患者发生TE的风险显著高于CD患者(OR 5.9,CI 1.56 - 22.33,P = 0.008)。受影响的女孩比男孩多(女:男 = 7:5),但未达到显著差异。约90%的患者在疾病活动期发生TE,12例患者中有6例出现相关的脑部和肢体受累。确定了各种风险因素,如住院、凝血病或贫血。TE的治疗包括重症监护和手术。12例患者中,11例完全康复,其中1例患者有局灶性癫痫后遗症。
IBD儿科患者发生TE的风险大幅增加。在管理儿科IBD时应考虑已确定的风险因素,如上述因素,并对住院患者常规采取预防措施。由于缺乏关于儿科IBD疗效和安全性的已发表试验,启动药物性血栓预防具有挑战性,但在每种情况下都应仔细考虑。